Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix’s AAGP™
News Jun 08, 2007
As a follow up to ProtoKinetix Inc.’s May 23, 2007 press release related to cryopreserved (or frozen) cells treated with AAGP™, in collaboration with the University of Helsinki, Finland, ProtoKinetix has recently finished a set of trials designed to determine whether AAGP™ treated cells could survive after preservation in refrigeration (4°C).
Commenting on the results, ProtoKinetix’s Director of Scientific Affairs, Dr. John Todd, stated, “After 3 days of preservation in refrigeration, untreated stem cells have a very high mortality rate. In the most recent experiments with the University of Helsinki, Finland, it was determined that AAGP™ can significantly reduce this cell death rate. AAGP™ demonstrated an impressive and repetitive 8 to 12 times increase in cell viability and survivability.”
Dr. Todd added, “These results are extremely important and encouraging for isolating the limited stem cell populations found in certain organs and tissues, such as umbilical cord blood and bone marrow. The implications for the treatment of certain types of cancers, such as leukemia and other conditions requiring bone marrow transplant are enormous.”
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.